OoCs
Build the whole industry chain ecosystem of organ chip technology, insight into the mystery of life science, help medical science and technology reform, and meet the individual needs of patients.
Recent news
On December 16, 2025, the U.S. Senate overwhelmingly passed the FDA Modernization Act 3.0 (S355), adding yet another significant boost to the FDA’s intensive rollout of non-clinical trial support policies this year. Since the beginning of this year, the FDA, together with agencies such as the NIH, has introduced a series of measures—from supporting project applications to drafting technical guidance—continuously paving the way for cutting-edge technologies such as organoids and organ-on-a-chip.
The editorial titled “2025: Research in Review,” published in Nature Biotechnology on December 5, 2025, summarizes the top ten biotechnology research breakthroughs selected by the editors. Overall, biotechnology in 2025 is characterized by an accelerating convergence among gene editing, cell and gene therapies, immunotherapy, and artificial intelligence (AI). CRISPR-based editing tools have become more precise and clinically relevant, while the field of biotechnology continues to push the boundaries of immunotherapy. Quantum computing has also made it onto the list of our most popular articles published this year.
On December 2, the U.S. FDA website released a draft guidance titled “Monoclonal Antibodies: Streamlining Nonclinical Safety Studies,” which clarifies that nonclinical safety assessments for monospecific monoclonal antibodies (mAbs) can significantly reduce the need for nonhuman primate studies. This policy leverages organ-on-chip and organoid technologies, computational toxicology, and real-world human data to build a toxicity assessment framework.
©2023 Jiangsu Avatarget Biotechnology Co., Ltd. All rights reserved Website Construction:China Enterprise Power Kunshan SEO
Business License
We use optional cookies to improve your experience on our website, including through social media connections, and to personalize ads based on your online activity. If you refuse optional cookies, we will only use cookies that are necessary to provide you with the services.Privacy Statement
